• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

临床和 CT 定量特征预测胰腺神经内分泌肿瘤患者肝转移:一项前瞻性/外部验证研究。

Clinical and CT Quantitative Features for Predicting Liver Metastases in Patients with Pancreatic Neuroendocrine Tumors: A Study with Prospective/External Validation.

机构信息

Department of Radiology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310009, China.

Department of Radiology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China.

出版信息

Acad Radiol. 2024 Sep;31(9):3612-3619. doi: 10.1016/j.acra.2024.02.002. Epub 2024 Mar 15.

DOI:10.1016/j.acra.2024.02.002
PMID:38490841
Abstract

RATIONALE AND OBJECTIVES

We aimed to evaluate clinical characteristics and quantitative CT imaging features for the prediction of liver metastases (LMs) in patients with pancreatic neuroendocrine tumors (PNETs).

METHODS

Patients diagnosed with pathologically confirmed PNETs were included, 133 patients were in the training group, 22 patients in the prospective internal validation group, and 28 patients in the external validation group. Clinical information and quantitative features were collected. The independent variables for predicting LMs were confirmed through the implementation of univariate and multivariate logistic analyses. The diagnostic performance was evaluated by conducting receiver operating characteristic curves for predicting LMs in the training and validation groups.

RESULTS

PNETs with LMs demonstrated significantly larger diameter and lower arterial/portal tumor-parenchymal enhancement ratio, arterial/portal absolute enhancement value (AAE/PAE value) (p < 0.05). After multivariate analyses, A high level of tumor marker (odds ratio (OR): 5.32; 95% CI, 1.54-18.35), maximum diameter larger than 24.6 mm (OR: 7.46; 95% CI, 1.70-32.72), and AAE value ≤ 51 HU (OR: 4.99; 95% CI, 0.93-26.95) were independent positive predictors of LMs in patients with PNETs, with area under curve (AUC) of 0.852 (95%CI, 0.781-0.907). The AUCs for prospective internal and external validation groups were 0.883 (95% CI, 0.686-0.977) and 0.789 (95% CI, 0.602-0.916), respectively.

CONCLUSION

Tumor marker, maximum diameter and absolute enhancement value in arterial phase were independent predictors with good predictive performance for the prediction of LMs in patients with PNETs. Combining clinical and quantitative features may facilitate the attainment of good predictive precision in predicting LMs.

摘要

背景与目的

本研究旨在评估胰腺神经内分泌肿瘤(pancreatic neuroendocrine tumors,PNETs)患者发生肝转移(liver metastases,LMs)的临床特征和定量 CT 成像特征,以便预测 LMs。

方法

纳入经病理证实的 PNETs 患者,其中 133 例患者纳入训练组,22 例患者纳入前瞻性内部验证组,28 例患者纳入外部验证组。收集临床信息和定量特征。采用单因素和多因素逻辑分析确定预测 LMs 的独立变量。通过在训练组和验证组中进行受试者工作特征曲线(receiver operating characteristic curves)评估预测 LMs 的诊断性能。

结果

发生 LMs 的 PNETs 肿瘤直径显著更大,动脉/门脉肿瘤-实质增强比值、动脉/门脉绝对增强值(arterial/portal absolute enhancement value,AAE/PAE value)更低(p<0.05)。多因素分析后,肿瘤标志物水平较高(比值比(odds ratio,OR):5.32;95%置信区间,1.54-18.35)、最大直径大于 24.6mm(OR:7.46;95%置信区间,1.70-32.72)、AAE 值≤51HU(OR:4.99;95%置信区间,0.93-26.95)是 PNETs 患者发生 LMs 的独立阳性预测因素,曲线下面积(area under the curve,AUC)为 0.852(95%置信区间,0.781-0.907)。前瞻性内部和外部验证组的 AUC 分别为 0.883(95%置信区间,0.686-0.977)和 0.789(95%置信区间,0.602-0.916)。

结论

肿瘤标志物、最大直径和动脉期绝对增强值是预测 PNETs 患者发生 LMs 的独立预测因素,具有良好的预测效能。结合临床和定量特征可能有助于提高预测 LMs 的预测精度。

相似文献

1
Clinical and CT Quantitative Features for Predicting Liver Metastases in Patients with Pancreatic Neuroendocrine Tumors: A Study with Prospective/External Validation.临床和 CT 定量特征预测胰腺神经内分泌肿瘤患者肝转移:一项前瞻性/外部验证研究。
Acad Radiol. 2024 Sep;31(9):3612-3619. doi: 10.1016/j.acra.2024.02.002. Epub 2024 Mar 15.
2
Quantitative analysis of enhanced CT in differentiating well-differentiated pancreatic neuroendocrine tumors and poorly differentiated neuroendocrine carcinomas.增强 CT 定量分析在鉴别高分化胰腺神经内分泌肿瘤和低分化神经内分泌癌中的应用。
Eur Radiol. 2022 Dec;32(12):8317-8325. doi: 10.1007/s00330-022-08891-4. Epub 2022 Jun 27.
3
The prognostic value of multidetector CT features in predicting overall survival outcomes in patients with pancreatic neuroendocrine tumors.多排螺旋 CT 特征对预测胰腺神经内分泌肿瘤患者总生存结局的预后价值。
Eur J Radiol. 2020 Mar;124:108847. doi: 10.1016/j.ejrad.2020.108847. Epub 2020 Jan 23.
4
Pancreatic neuroendocrine tumors: MR imaging features preoperatively predict lymph node metastasis.胰腺神经内分泌肿瘤:术前磁共振成像特征可预测淋巴结转移。
Abdom Radiol (NY). 2019 Mar;44(3):1000-1009. doi: 10.1007/s00261-018-1863-y.
5
The value of a nomogram model based on CT imaging features in differentiating duodenal gastrointestinal stromal tumors from pancreatic head neuroendocrine tumors.基于CT成像特征的列线图模型在鉴别十二指肠胃肠道间质瘤与胰头神经内分泌肿瘤中的价值
Abdom Radiol (NY). 2025 Mar;50(3):1330-1341. doi: 10.1007/s00261-024-04579-z. Epub 2024 Sep 20.
6
The value of serum chromogranin A as a predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases.血清嗜铬粒蛋白A在伴有肝转移的中低级别无功能胰腺神经内分泌肿瘤中作为肿瘤负荷、治疗反应及基于列线图的生存预测指标的价值。
Eur J Gastroenterol Hepatol. 2015 May;27(5):527-35. doi: 10.1097/MEG.0000000000000332.
7
Differentiation between non-hypervascular pancreatic neuroendocrine tumors and mass-forming pancreatitis using contrast-enhanced computed tomography.使用增强 CT 鉴别非富血供胰腺神经内分泌肿瘤和肿块型胰腺炎。
Acta Radiol. 2021 Feb;62(2):190-197. doi: 10.1177/0284185120921503. Epub 2020 May 6.
8
Comparison between neuroendocrine carcinomas and well-differentiated neuroendocrine tumors of the pancreas using dynamic enhanced CT.应用动态增强 CT 对胰腺神经内分泌癌和高分化神经内分泌肿瘤进行比较。
Eur Radiol. 2020 Sep;30(9):4772-4782. doi: 10.1007/s00330-020-06867-w. Epub 2020 Apr 28.
9
Nonhypervascular pancreatic neuroendocrine tumors: Spectrum of MDCT imaging findings and differentiation from pancreatic ductal adenocarcinoma.非富血供胰腺神经内分泌肿瘤:MDCT 成像表现谱及与胰腺导管腺癌的鉴别诊断。
Eur J Radiol. 2019 Jan;110:66-73. doi: 10.1016/j.ejrad.2018.04.006. Epub 2018 Apr 11.
10
Grade 3 Pancreatic Neuroendocrine Tumors on MDCT: Establishing a Diagnostic Model and Comparing Survival Against Pancreatic Ductal Adenocarcinoma.MDCT 分级 3 胰腺神经内分泌肿瘤:建立诊断模型并与胰腺导管腺癌的生存情况进行比较。
AJR Am J Roentgenol. 2020 Aug;215(2):390-397. doi: 10.2214/AJR.19.21921. Epub 2020 May 20.